Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Oppenheimer healthcare analysts hold an analyst/industry conference call » 04:55
11/18/21
11/18
04:55
11/18/21
04:55
AZN

AstraZeneca

$57.72 /

+0.08 (+0.14%)

, SNY

Sanofi

$51.04 /

+0.14 (+0.28%)

, JNJ

Johnson & Johnson

$163.29 /

+0.63 (+0.39%)

, PFE

Pfizer

$50.88 /

+1.305 (+2.63%)

, NVS

Novartis

$81.93 /

-0.03 (-0.04%)

, RHHBY

Roche

$49.86 /

+0.25 (+0.50%)

, LLY

Eli Lilly

$261.12 /

+3.435 (+1.33%)

, ARVN

Arvinas

$81.47 /

+1.59 (+1.99%)

, EPIX

Essa Pharma

$13.00 /

-0.31 (-2.33%)

, FMTX

Forma Therapeutics

$18.56 /

+0.46 (+2.54%)

, MBIO

Mustang Bio

$2.26 /

-0.065 (-2.80%)

, MGNX

MacroGenics

$19.15 /

-0.12 (-0.62%)

, VERU

Veru

$8.65 /

-0.38 (-4.21%)

Healthcare Analysts…

Healthcare Analysts discuss Prostate Cancer Therapeutics, (relevant for companies AZN, SNY, JNJ, PFE, NVS, RHHBY, LLY, ARVN, EPIX, FMTX, MBIO, MGNX and VERU) on an Analyst/Industry conference call to be held on November 18.

ShowHide Related Items >><<
VERU Veru
$8.65 /

-0.38 (-4.21%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

RHHBY Roche
$49.86 /

+0.25 (+0.50%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

NVS Novartis
$81.93 /

-0.03 (-0.04%)

MGNX MacroGenics
$19.15 /

-0.12 (-0.62%)

MBIO Mustang Bio
$2.26 /

-0.065 (-2.80%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

FMTX Forma Therapeutics
$18.56 /

+0.46 (+2.54%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

ARVN Arvinas
$81.47 /

+1.59 (+1.99%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
SNY Sanofi
$51.04 /

+0.14 (+0.28%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
PFE Pfizer
$50.88 /

+1.305 (+2.63%)

11/17/21 Benchmark
Trillium Therapeutics downgraded to Hold from Buy at Benchmark
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
NVS Novartis
$81.93 /

-0.03 (-0.04%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
RHHBY Roche
$49.86 /

+0.25 (+0.50%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
ARVN Arvinas
$81.47 /

+1.59 (+1.99%)

11/04/21 Oppenheimer
Arvinas upgraded to Outperform from Perform at Oppenheimer
10/20/21 Stifel
Success of Radius' elacestrant lowers risk for Arvinas' ARV-471, says Stifel
10/14/21 SVB Leerink
Arvinas initiated with an Outperform at SVB Leerink
09/29/21 Stifel
Arvinas initiated with a Buy at Stifel
EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
FMTX Forma Therapeutics
$18.56 /

+0.46 (+2.54%)

10/07/21 Oppenheimer
Forma Therapeutics' FT-7051 'high encouraging', says Oppenheimer
08/17/21 H.C. Wainwright
Forma Therapeutics price target lowered to $53 from $55 at H.C. Wainwright
08/02/21
Fly Intel: Top five analyst initiations
08/02/21 Craig-Hallum
Forma Therapeutics initiated with a Buy at Craig-Hallum
MBIO Mustang Bio
$2.26 /

-0.065 (-2.80%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MGNX MacroGenics
$19.15 /

-0.12 (-0.62%)

11/17/21 Guggenheim
MacroGenics assumed with a Buy at Guggenheim
10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
VERU Veru
$8.65 /

-0.38 (-4.21%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$8.65 /

-0.38 (-4.21%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

RHHBY Roche
$49.86 /

+0.25 (+0.50%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

NVS Novartis
$81.93 /

-0.03 (-0.04%)

MGNX MacroGenics
$19.15 /

-0.12 (-0.62%)

MBIO Mustang Bio
$2.26 /

-0.065 (-2.80%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

FMTX Forma Therapeutics
$18.56 /

+0.46 (+2.54%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

ARVN Arvinas
$81.47 /

+1.59 (+1.99%)

  • 18
    Feb
  • 18
    Feb
  • 16
    Dec
  • 11
    Dec
SNY Sanofi
$51.04 /

+0.14 (+0.28%)

RHHBY Roche
$49.86 /

+0.25 (+0.50%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

NVS Novartis
$81.93 /

-0.03 (-0.04%)

JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

SNY Sanofi
$51.04 /

+0.14 (+0.28%)

RHHBY Roche
$49.86 /

+0.25 (+0.50%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

NVS Novartis
$81.93 /

-0.03 (-0.04%)

MGNX MacroGenics
$19.15 /

-0.12 (-0.62%)

MBIO Mustang Bio
$2.26 /

-0.065 (-2.80%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

PFE Pfizer
$50.88 /

+1.305 (+2.63%)

NVS Novartis
$81.93 /

-0.03 (-0.04%)

LLY Eli Lilly
$261.12 /

+3.435 (+1.33%)

JNJ Johnson & Johnson
$163.29 /

+0.63 (+0.39%)

EPIX Essa Pharma
$13.00 /

-0.31 (-2.33%)

AZN AstraZeneca
$57.72 /

+0.08 (+0.14%)

Earnings
Mustang Bio reports Q3 EPS (19c), consensus (18c) » 08:15
11/12/21
11/12
08:15
11/12/21
08:15
MBIO

Mustang Bio

$2.48 /

+ (+0.00%)

As of September 30, 2021,…

As of September 30, 2021, Mustang's cash and cash equivalents and restricted cash totaled $121.9 million, compared to $130.9 million at June 30, 2021. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "Mustang continued to advance the development of our CAR T therapies across multiple cancers, as well as our lentiviral gene therapies, in the third quarter of 2021. In the MB-106 abstract posted earlier this month on the American Society of Hematology Annual Meeting website, data from 16 patients further indicate that MB-106 CD20-targeted autologous CAR T cell therapy has a favorable safety profile as outpatient therapy, with compelling clinical activity, ongoing durable complete responses and a high rate of CAR T persistence. The overall response rate was 94% with a complete response rate of 62%. In patients with follicular lymphoma, ORR was 92% and CR rate was 75%. We look forward to disclosing additional interim MB-106 clinical data at ASH2021 and to enrolling the first patient in the clinical trial under Mustang's investigational new drug trial to further advance MB-106 for patients with relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia. Earlier this month, we also announced that Mustang received a National Cancer Institute two-year grant to support our ongoing research and development of MB-106. We anticipate providing additional updates on our CAR T and gene therapy clinical programs in the coming months," Dr. Litchman concluded.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.48 /

+ (+0.00%)

MBIO Mustang Bio
$2.48 /

+ (+0.00%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.48 /

+ (+0.00%)

MBIO Mustang Bio
$2.48 /

+ (+0.00%)

Hot Stocks
Mustang Bio announces exclusive worldwide license agreement with LUMC » 08:56
11/10/21
11/10
08:56
11/10/21
08:56
MBIO

Mustang Bio

$2.55 /

+0.15 (+6.25%)

Mustang Bio announced…

Mustang Bio announced that the company has executed an exclusive license agreement with Leiden University Medical Centre, LUMC, for a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency, RAG1-SCID. The therapy, which includes low-dose conditioning prior to reinfusion of the patients' own gene-modified blood stem cells, is currently being evaluated in a Phase 1/2 multicenter clinical trial in Europe. The ongoing clinical trial recently enrolled its first patient, and additional clinical sites are expected to be added in the near future. The RAG1-SCID program has been granted Orphan Drug Designation by the European Medicines Agency. Mustang also established an ongoing partnership with Frank Staal, Ph.D., professor of Molecular Stem Cell Biology and molecular immunologist. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang said, "We are excited to add RAG1-SCID to the Mustang portfolio as it enables us to leverage our lentiviral gene therapy expertise and experience and our state-of-the-art cell processing facility. Mustang is establishing itself as the leader in developing treatments for patients with severe combined immunodeficiency, an area of high unmet need. We have made great progress in moving our XSCID therapy into a registrational trial and look forward to similarly advancing this RAG1-SCID therapy to make it available for patients in need of life-saving treatment."

ShowHide Related Items >><<
MBIO Mustang Bio
$2.55 /

+0.15 (+6.25%)

MBIO Mustang Bio
$2.55 /

+0.15 (+6.25%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.55 /

+0.15 (+6.25%)

MBIO Mustang Bio
$2.55 /

+0.15 (+6.25%)

Conference/Events
Oppenheimer healthcare analysts hold an analyst/industry conference call » 12:55
11/09/21
11/09
12:55
11/09/21
12:55
AZN

AstraZeneca

$62.84 /

-0.16 (-0.25%)

, SNY

Sanofi

$51.26 /

+0.135 (+0.26%)

, JNJ

Johnson & Johnson

$162.73 /

-0.18 (-0.11%)

, PFE

Pfizer

$47.22 /

-1.11 (-2.30%)

, NVS

Novartis

$83.13 /

-0.1 (-0.12%)

, RHHBY

Roche

$50.21 /

+0.01 (+0.02%)

, LLY

Eli Lilly

$260.73 /

+0.18 (+0.07%)

, ARVN

Arvinas

$92.15 /

-0.62 (-0.67%)

, EPIX

Essa Pharma

$10.25 /

-0.3 (-2.84%)

, FMTX

Forma Therapeutics

$18.75 /

-0.19 (-1.00%)

, MBIO

Mustang Bio

$2.53 /

+0.13 (+5.42%)

, MGNX

MacroGenics

$21.53 /

+0.68 (+3.26%)

, VERU

Veru

$8.58 /

-0.08 (-0.92%)

Healthcare Analysts…

Healthcare Analysts discuss Prostate Cancer Therapeutics, (relevant for companies AZN, SNY, JNJ, PFE, NVS, RHHBY, LLY, ARVN, EPIX, FMTX, MBIO, MGNX and VERU) on an Analyst/Industry conference call to be held on November 18.

ShowHide Related Items >><<
VERU Veru
$8.58 /

-0.08 (-0.92%)

SNY Sanofi
$51.26 /

+0.135 (+0.26%)

RHHBY Roche
$50.21 /

+0.01 (+0.02%)

PFE Pfizer
$47.22 /

-1.11 (-2.30%)

NVS Novartis
$83.13 /

-0.1 (-0.12%)

MGNX MacroGenics
$21.53 /

+0.68 (+3.26%)

MBIO Mustang Bio
$2.53 /

+0.13 (+5.42%)

LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

FMTX Forma Therapeutics
$18.75 /

-0.19 (-1.00%)

EPIX Essa Pharma
$10.25 /

-0.3 (-2.84%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

ARVN Arvinas
$92.15 /

-0.62 (-0.67%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
SNY Sanofi
$51.26 /

+0.135 (+0.26%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
PFE Pfizer
$47.22 /

-1.11 (-2.30%)

11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
NVS Novartis
$83.13 /

-0.1 (-0.12%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
RHHBY Roche
$50.21 /

+0.01 (+0.02%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
ARVN Arvinas
$92.15 /

-0.62 (-0.67%)

11/04/21 Oppenheimer
Arvinas upgraded to Outperform from Perform at Oppenheimer
10/20/21 Stifel
Success of Radius' elacestrant lowers risk for Arvinas' ARV-471, says Stifel
10/14/21 SVB Leerink
Arvinas initiated with an Outperform at SVB Leerink
09/29/21 Stifel
Arvinas initiated with a Buy at Stifel
EPIX Essa Pharma
$10.25 /

-0.3 (-2.84%)

08/16/21 Oppenheimer
Essa Pharma price target lowered to $22 from $36 at Oppenheimer
08/16/21 Piper Sandler
Essa Pharma readout delay raises some concerns, says Pper Sandler
04/23/21 Piper Sandler
Essa Pharma transferred with Overweight at Piper Sandler
03/04/21
Fly Intel: Top five analyst initiations
FMTX Forma Therapeutics
$18.75 /

-0.19 (-1.00%)

10/07/21 Oppenheimer
Forma Therapeutics' FT-7051 'high encouraging', says Oppenheimer
08/17/21 H.C. Wainwright
Forma Therapeutics price target lowered to $53 from $55 at H.C. Wainwright
08/02/21
Fly Intel: Top five analyst initiations
08/02/21 Craig-Hallum
Forma Therapeutics initiated with a Buy at Craig-Hallum
MBIO Mustang Bio
$2.53 /

+0.13 (+5.42%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MGNX MacroGenics
$21.53 /

+0.68 (+3.26%)

10/19/21 JMP Securities
MacroGenics initiated with an Outperform at JMP Securities
10/14/21 BTIG
MacroGenics assumed with a Buy at BTIG
06/07/21 Wedbush
MacroGenics price target lowered to $34 from $39 at Wedbush
04/30/21 H.C. Wainwright
MacroGenics price target raised to $41 from $36 at H.C. Wainwright
VERU Veru
$8.58 /

-0.08 (-0.92%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$8.58 /

-0.08 (-0.92%)

SNY Sanofi
$51.26 /

+0.135 (+0.26%)

RHHBY Roche
$50.21 /

+0.01 (+0.02%)

PFE Pfizer
$47.22 /

-1.11 (-2.30%)

NVS Novartis
$83.13 /

-0.1 (-0.12%)

MGNX MacroGenics
$21.53 /

+0.68 (+3.26%)

MBIO Mustang Bio
$2.53 /

+0.13 (+5.42%)

LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

FMTX Forma Therapeutics
$18.75 /

-0.19 (-1.00%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

ARVN Arvinas
$92.15 /

-0.62 (-0.67%)

  • 18
    Feb
  • 18
    Feb
  • 16
    Dec
  • 11
    Dec
SNY Sanofi
$51.26 /

+0.135 (+0.26%)

RHHBY Roche
$50.21 /

+0.01 (+0.02%)

PFE Pfizer
$47.22 /

-1.11 (-2.30%)

NVS Novartis
$83.13 /

-0.1 (-0.12%)

LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

SNY Sanofi
$51.26 /

+0.135 (+0.26%)

RHHBY Roche
$50.21 /

+0.01 (+0.02%)

PFE Pfizer
$47.22 /

-1.11 (-2.30%)

NVS Novartis
$83.13 /

-0.1 (-0.12%)

MGNX MacroGenics
$21.53 /

+0.68 (+3.26%)

MBIO Mustang Bio
$2.53 /

+0.13 (+5.42%)

LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

EPIX Essa Pharma
$10.25 /

-0.3 (-2.84%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

PFE Pfizer
$47.22 /

-1.11 (-2.30%)

NVS Novartis
$83.13 /

-0.1 (-0.12%)

LLY Eli Lilly
$260.73 /

+0.18 (+0.07%)

JNJ Johnson & Johnson
$162.73 /

-0.18 (-0.11%)

EPIX Essa Pharma
$10.25 /

-0.3 (-2.84%)

AZN AstraZeneca
$62.84 /

-0.16 (-0.25%)

Hot Stocks
Mustang Bio announces MB-106 data selected for presentation at ASH » 09:43
11/04/21
11/04
09:43
11/04/21
09:43
MBIO

Mustang Bio

$2.48 /

+ (+0.00%)

Mustang Bio announced…

Mustang Bio announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas, NHL, and chronic lymphocytic leukemia, CCL, have been selected for a poster presentation at the 63rd American Society of Hematology Annual Meeting, which is being held from December 11-14, 2021. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center. The abstract posted today on the ASH2021 website reported on 16 patients treated following a major cell manufacturing process modification. CAR T cells are administered at one of 4 dose levels, DL: DL1: 3.3x105, DL2: 1x106, DL3: 3.3x106, DL4: 1x107 CAR T cells/kg. All DLs were reached, with no dose-limiting toxicities observed to date. The overall response rate, ORR, was 94% with a complete response, CR, rate of 62%. In patients with FL, ORR was 92% and CR rate was 75%. Among patients with FL who received DL 3 or 4, the CR rate was 86%. The patient with CLL had a PET-negative CR and undetectable measurable residual disease in peripheral blood and bone marrow by flow cytometry at a sensitivity of 10-4 on day 28. The patient with DLBCL achieved a partial response on day 28, and a repeat PET on day ~90 showed deepening of the PR. Among patients who achieved a CR, only one patient with FL relapsed after 9 months. All other CRs are ongoing. CAR T persistence was lost at day 95 in one patient who had progression and proceeded to other anti-lymphoma treatment; 2 other patients lost CAR T engraftment by day 181 and 201 with B-cell recovery. All other patients continue to have detectable CAR T cells as of last follow-up. Among the 16 total patients reported in the abstract, there were seven occurrences of cytokine release syndrome and one occurrence of Grade 2 immune effector cell-associated neurotoxicity syndrome. One patient with CLL developed Grade 3 temporary neuropathic pain which, in the absence of other explanation, was attributed to CAR T therapy. No patients had tumor lysis syndrome or Grade 3-4 infections. Thrombocytopenia and neutropenia were common, but there were no bleeding complications, and the rate of febrile neutropenia was 19%.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.48 /

+ (+0.00%)

MBIO Mustang Bio
$2.48 /

+ (+0.00%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.48 /

+ (+0.00%)

MBIO Mustang Bio
$2.48 /

+ (+0.00%)

Over a month ago
Hot Stocks
Mustang Bio awarded $2M NIH grant for MB-106 » 08:36
11/01/21
11/01
08:36
11/01/21
08:36
MBIO

Mustang Bio

$2.24 /

-0.035 (-1.54%)

Mustang Bio announced…

Mustang Bio announced that the company has been awarded a grant of approximately $2M from the National Cancer Institute of the National Institutes of Health, NIH. This two-year award will partially fund the Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia. In addition, the Office for Human Research Protections has approved Federalwide Assurance, FWA, for Mustang's research. FWA is an assurance of compliance with the U.S. federal regulations for the protection of human subjects in research. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "The NIH grant and FWA validate our scientific efforts as we continue to advance the development of MB-106. This grant will contribute to Mustang's evaluation of MB-106 in clinical trials with the hope to bring this therapeutic treatment to patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia."

ShowHide Related Items >><<
MBIO Mustang Bio
$2.24 /

-0.035 (-1.54%)

MBIO Mustang Bio
$2.24 /

-0.035 (-1.54%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.24 /

-0.035 (-1.54%)

MBIO Mustang Bio
$2.24 /

-0.035 (-1.54%)

Conference/Events
Mustang Bio management to meet virtually with BTIG » 04:55
10/18/21
10/18
04:55
10/18/21
04:55
MBIO

Mustang Bio

$2.29 /

-0.04 (-1.72%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by BTIG.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.29 /

-0.04 (-1.72%)

MBIO Mustang Bio
$2.29 /

-0.04 (-1.72%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.29 /

-0.04 (-1.72%)

MBIO Mustang Bio
$2.29 /

-0.04 (-1.72%)

Conference/Events
Mustang Bio management to meet virtually with BTIG » 09:54
10/11/21
10/11
09:54
10/11/21
09:54
MBIO

Mustang Bio

$2.25 /

-0.03 (-1.32%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by BTIG.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.25 /

-0.03 (-1.32%)

MBIO Mustang Bio
$2.25 /

-0.03 (-1.32%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.25 /

-0.03 (-1.32%)

MBIO Mustang Bio
$2.25 /

-0.03 (-1.32%)

Over a quarter ago
Hot Stocks
Mustang Bio collaborates with Mayo Clinic on Car T technology » 16:46
08/12/21
08/12
16:46
08/12/21
16:46
MBIO

Mustang Bio

$2.79 /

-0.03 (-1.07%)

Mustang Bio announced…

Mustang Bio announced that the company has executed an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of chimeric antigen receptor engineered T cell therapies and potentially be used as an off-the-shelf therapy. The technology, developed by Larry R. Pease, Ph.D., principal investigator and former director of the Center for Immunology and Immune Therapies at Mayo Clinic, is a new platform to administer CAR T therapy using a two-step approach. First, a peptide is administered to the patient to drive the proliferation of the patient's resident T cells. This is followed by the administration of a viral CAR construct directly into the lymph nodes of the patient. In turn, the viral construct infects the activated T cells and effectively forms CAR T cells in vivo in the patient. Successful implementation may lead to an off-the-shelf product with no need to isolate and expand patient T cells ex vivo. "We are excited by the possibilities that this novel technology has to offer given our ongoing development of CAR T cell therapies in hematologic and solid tumor cancers," said Manuel Litchman, M.D., President and CEO of Mustang. "The potential use of this technology to facilitate how these treatments are delivered to patients can lead to earlier treatment post diagnosis, and using an off-the-shelf therapy may reduce the cost of care, all of which would help bring more innovative treatments to a broader base of patients in need." Mustang plans to file an Investigational New Drug application for a multicenter Phase 1 clinical trial once a lead construct has been identified.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.79 /

-0.03 (-1.07%)

MBIO Mustang Bio
$2.79 /

-0.03 (-1.07%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.79 /

-0.03 (-1.07%)

MBIO Mustang Bio
$2.79 /

-0.03 (-1.07%)

Hot Stocks
Mustang Bio receives European Medicines Agency PRIME designation for MB-107 » 08:23
08/02/21
08/02
08:23
08/02/21
08:23
MBIO

Mustang Bio

$2.89 /

-0.02 (-0.69%)

Mustang Bio announced…

Mustang Bio announced that the European Medicines Agency has granted Priority Medicines designation to MB-107, its lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency in newly diagnosed infants, also known as bubble boy disease. In addition to PRIME designation, the EMA granted Advanced Therapy Medicinal Product classification to MB-107 in April 2020 and Orphan Drug designation in November 2020. MB-107 has also received Orphan Drug, Rare Pediatric Disease and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration. "We are very pleased that the EMA continues to acknowledge the potential for MB-107 to be a new treatment option for patients with XSCID, a devastating rare disease," said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. "Receiving PRIME designation is an exciting milestone for Mustang as we prepare to initiate a pivotal, multicenter Phase 2 clinical trial of MB-107 in newly diagnosed patients with XSCID at the end of this quarter. We look forward to having a kick-off meeting with the Committee on Advanced Therapies and its multidisciplinary group of experts to provide additional guidance on our overall MB-107 development plan and regulatory strategy to potentially further expedite clinical development and approval in Europe." The same lentiviral vector used in MB-107 is currently being assessed in an ongoing Phase 1/2 clinical trial for XSCID in newly diagnosed infants under 2 years of age at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospital and Seattle Children's Hospital.

ShowHide Related Items >><<
MBIO Mustang Bio
$2.89 /

-0.02 (-0.69%)

MBIO Mustang Bio
$2.89 /

-0.02 (-0.69%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
MBIO Mustang Bio
$2.89 /

-0.02 (-0.69%)

MBIO Mustang Bio
$2.89 /

-0.02 (-0.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.